Merck KGaA’s Biopharmaceutical Division Appoints New Global Head of R&D
Merck KGaA’s biopharmaceutical division today announced the appointment of Luciano Rossetti, M.D., as Executive Vice President and Global Head of Research & Development as of July 21, 2014.
In his most recent role Rossetti (57) acted as Senior Vice President Late Stage Development at Merck Sharp & Dohme, or MSD (in the U.S. Merck & Co.). In this position, he was responsible for the entire clinical development from Phase II to Phase V across all therapeutic areas. At MSD, he played a key role in shaping and implementing the development strategy of several potential breakthrough compounds such as anti PD-1. He also restructured the clinical genetics group to better leverage the collaboration between discovery and clinical development. Before joining MSD in 2006, Rossetti was an internationally recognized academic scientist for 18 years.
“I’m thrilled to welcome Luciano Rossetti to our division,” said Belén Garijo, President and CEO at the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. “His breadth of experience and solid track record in both research as well as development together with his distinct leadership profile will be instrumental in driving the development of our promising pipeline to ensure that we will meet our strategic milestones and deliver innovative solutions for unmet medical needs to patients around the world.“
Rossetti will be based in Billerica, outside Boston, Massachusetts (U.S.), and share his time between Merck KGaA’s headquarters in Darmstadt (Germany) and Billerica – one of the company’s biopharmaceutical division’s four global R&D hubs.